- $722.30m
- $513.05m
Annexon extends gains after launching stock offering to fund neurological disorder drug
Annexon drops after launching $125 mln stock offering to fund neurological disorder drug
U.S. RESEARCH ROUNDUP-Abbvie, Lionsgate Studios, UnitedHealth Group
U.S. STOCKS ON THE MOVE-Paramount Global, Core Scientific, Amarin
Newscasts - Gaza border closure leaves child cancer patient helpless
U.S. STOCKS ON THE MOVE-Core & Main, HEICO, Honeywell
U.S. STOCKS ON THE MOVE-GameStop, Annexon, Viking Therapeutics
U.S. STOCKS ON THE MOVE-Intel, HealthEquity, Donaldson
Annexon jumps as neuromuscular disease drug succeeds in late-stage trial
Annexon's neurological disease drug meets main goal of late-stage study (updated)
Annexon's neurological disorder drug meets main goal of late-stage study
U.S. RESEARCH ROUNDUP- Altus Power, Jack in the Box, Home Depot
U.S. RESEARCH ROUNDUP- Altus Power, Jack in the Box, Home Depot
U.S. STOCKS ON THE MOVE-Annexon, MKS Instruments, Robinhood
Annexon Inc reports results for the quarter ended in March - Earnings Summary
Annexon rises after Q1 loss narrows
Annexon Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Turnstone Biologics Appoints William Waddill To Its Board Of Directors
Brief: Annexon Inc Says Entered Sales Agreement Relating To Sale Of Shares Of Common Stock, May Offer Shares Of Common Stock, From Time To Time, For $100 Million